Biohaven Pharmaceutical Holding Company Ltd said its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.
https://www.pharmalive.com/wp-content/uploads/2021/12/Biohavens-migraine-therapy-shows-rapid-pain-relief-in-late-stage-study-Reuters-12-6-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-29 08:39:512022-09-29 09:43:12Biohaven’s ALS drug fails to meet study goals
